Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
- Andres Forero-Torres
- , Jatin Shah
- , Tina Wood
- , James Posey
- , Ronda Carlisle
- , Catherine Copigneaux
- , F. Luo
- , Slawomir Wojtowicz-Praga
- , Ivor Percent
- , Mansoor Saleh
Research output: Contribution to journal › Article › peer-review
135
Citations
(Scopus)